Scholar Rock Holding Corporation SRRK
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- -2.59%
- 1 year
- +44.87%
- Open
- 44.13
- Prev close
- 43.90
- Mkt cap
- 5.23B
- Vol
- 932.04K
- Avg vol
- 1.67M
- EPS
- -3.25
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 42.89
- High
- 44.78
- Forward P/E
- -17.29
- Beta
- 0.79
- Short ratio
- 9.77
- Inst. own
- 118.34%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 10, 2026
- 50-d avg
- 48.47
- 200-d avg
- 48.21
- 1y target
- 70.44
News
1 week ago gurufocus.com
Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026
Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2026 financial results on Tuesday, November 10, 2026, before the financial markets
2 weeks ago businesswire.com
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the Company granted inducement equity awards covering an aggregate of 61,020 shares of its common…
-
3 weeks ago benzinga.com
Scholar Rock Refiles Marketing Authorisation Application With EMA For Apitegromab To Treat Children And Adults With Spinal Muscular Atrophy
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading…
3 weeks ago businesswire.com
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular…
3 weeks ago defenseworld.net
Scholar Rock (NASDAQ:SRRK) Stock Falls 5.1% – Here’s What Happened
Shares of Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) traded down 5.1% on Monday. The stock traded as low as $44.59 and last traded at $44.4380. Approximately 908,652 shares…
4 weeks ago benzinga.com
Scholar Rock Holding Reports Q2 2026 Results: Full Earnings Call Transcript
Scholar Rock Holding (NASDAQ:SRRK) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga…
1 month ago prnewswire.com
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Scholar Rock Holding Corp (NASDAQ: SRRK)…
-
1 month ago benzinga.com
Truist Securities Maintains Buy on Scholar Rock Holding, Raises Price Target to $77
Truist Securities analyst Srikripa Devarakonda maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $76 to $77.
1 month ago businesswire.com
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 83,102 shares of its common…
-
1 month ago benzinga.com
JP Morgan Maintains Overweight on Scholar Rock Holding, Raises Price Target to $70
JP Morgan analyst Tessa Romero maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $63 to $70.
1 month ago defenseworld.net
Scholar Rock Holding Corporation $SRRK Shares Bought by Engineers Gate Manager LP
Engineers Gate Manager LP lifted its stake in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK) by 211.3% during the second quarter, according to the company in its most recent disclosure…
1 month ago seekingalpha.com
Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play
Scholar Rock Holding Corporation maintains a "Strong Buy" rating following FDA approval of ISEMBYLD [apitegromab] for SMA in patients ≥2 years old. SRRK targets a $2B+ market opportunity in SMA, with…
-
1 month ago benzinga.com
Evercore ISI Group Maintains Outperform on Scholar Rock Holding, Raises Price Target to $72
Evercore ISI Group analyst Cory Kasimov maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and raises the price target from $65 to $72.
-
1 month ago benzinga.com
Piper Sandler Maintains Overweight on Scholar Rock Holding, Raises Price Target to $75
Piper Sandler analyst Allison Bratzel maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $60 to $75.
-
1 month ago benzinga.com
Jefferies Maintains Buy on Scholar Rock Holding, Raises Price Target to $65
Jefferies analyst Amy Li maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $57 to $65.
1 month ago benzinga.com
This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Analysts downgraded Banco Santander Brasil, Ribbon Communications, Cellectis, Scholar Rock, with mixed price-target changes.
-
1 month ago benzinga.com
Wedbush Maintains Outperform on Scholar Rock Holding, Raises Price Target to $70
Wedbush analyst David Nierengarten maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and raises the price target from $64 to $70.
1 month ago benzinga.com
Zebra Technologies To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
Analysts cut Exodus’ target, raised targets for Teledyne, Roblox, Scholar Rock, Zebra, Agilon, SM Energy and Paymentus; Agilon upgraded to Outperform.
-
1 month ago benzinga.com
Barclays Downgrades Scholar Rock Holding to Equal-Weight, Raises Price Target to $58
Barclays analyst Etzer Darout downgrades Scholar Rock Holding (NASDAQ:SRRK) from Overweight to Equal-Weight and raises the price target from $55 to $58.
1 month ago 247wallst.com
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Eli Lilly, Etsy, Lear, Netskope, Nokia, Northrop Grumman, Rapid7, Rivian Automotive, Ulta Beauty, and More
Markets are rattled ahead of Wednesday's Fed decision, and Wall Street analysts are making bold moves on names like Eli Lilly, Etsy, Northrop Grumman, and Rivian. Find out which stocks got upgraded,…
-
1 month ago benzinga.com
HC Wainwright & Co. Maintains Buy on Scholar Rock Holding, Raises Price Target to $70
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $65 to $70.
1 month ago seekingalpha.com
Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript
Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript
-
1 month ago benzinga.com
Raymond James Maintains Strong Buy on Scholar Rock Holding, Raises Price Target to $72
Raymond James analyst Gary Nachman maintains Scholar Rock Holding (NASDAQ:SRRK) with a Strong Buy and raises the price target from $65 to $72.
-
1 month ago benzinga.com
BMO Capital Maintains Outperform on Scholar Rock Holding, Raises Price Target to $84
BMO Capital analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and raises the price target from $76 to $84.
-
1 month ago benzinga.com
Truist Securities Reiterates Buy on Scholar Rock Holding, Raises Price Target to $76
Truist Securities analyst Srikripa Devarakonda reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $55 to $76.
-
1 month ago benzinga.com
Citigroup Maintains Buy on Scholar Rock Holding, Raises Price Target to $74
Citigroup analyst Geoff Meacham maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $60 to $74.
1 month ago benzinga.com
Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy
The U.S. Food and Drug Administration on Friday approved ISEMBYLD (apitegromab-mstn) from Scholar Rock (NASDAQ:SRRK) for spinal muscular atrophy (SMA) in adults and pediatric patients aged 2 years…
1 month ago benzinga.com
Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy
FDA approves Scholar Rock Isembyld to treat spinal muscular atrophy in adults and pediatric patients two years and older.
-
1 month ago benzinga.com
Wedbush Reiterates Outperform on Scholar Rock Holding, Maintains $64 Price Target
Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and maintains $64 price target.
1 month ago reuters.com
Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial
Scholar Rock on Monday set a list price of $11,659 per single-use vial for its newly approved spinal muscular atrophy drug, the first therapy that directly targets muscle loss in patients…
1 month ago benzinga.com
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Shares of Scholar Rock Holding Corp (NASDAQ:SRRK) rose sharply in pre-market trading after the company announced the FDA approval of ISEMBYLD (apitegromab-mstn), the first and only muscle-targeted…
1 month ago benzinga.com
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premarket gainers, while Picocela fell.
1 month ago businesswire.com
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular…
1 month ago reuters.com
US FDA approves Scholar Rock's muscle weakness drug
The U.S. Food and Drug Administration on Friday approved Scholar Rock's therapy to treat a rare genetic condition that causes muscle weakness.
1 month ago seekingalpha.com
Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Scholar Rock Holding, Maintains $65 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $65 price target.
1 month ago seekingalpha.com
Scholar Rock: Manufacturing Noise Obscures A Muscle-Targeted Franchise
Scholar Rock is positioned to launch apitegromab as the first muscle-targeted therapy for SMA, pending FDA approval by September 30, 2026. Manufacturing setbacks were production-based, not due to…
-
2 months ago benzinga.com
Scholar Rock Receives FDA's Fast Track And Orphan Drug Designations For Apitegromab To Treat Facioscapulohumeral Muscular Dystrophy
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading…
2 months ago businesswire.com
Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular…
2 months ago defenseworld.net
Beaconlight Capital LLC Makes New Investment in Scholar Rock Holding Corporation $SRRK
Beaconlight Capital LLC purchased a new stake in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK) during the second quarter, according to its most recent Form 13F filing with the Securities…
2 months ago defenseworld.net
9,494,084 Shares in Scholar Rock Holding Corporation $SRRK Purchased by BlackRock Inc.
BlackRock Inc. acquired a new position in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK) in the undefined quarter, according to its most recent filing with the SEC. The fund acquired…
-
2 months ago benzinga.com
Scholar Rock Removes Catalent Indiana As Commercial Fill-Finish Facility From Its Apitegromab BLA For The Treatment Of Spinal Muscular Atrophy Under Guidance From The FDA; Now On Track To Submit Apitegromab Japanese New Drug Application By End-2026
FDA review of BLA progressing well with Scholar Rock’s alternate fill-finish facilityCompany is prepared for U.S. apitegromab launch immediately upon FDA approval, which may be granted at any time…
-
2 months ago benzinga.com
JP Morgan Maintains Overweight on Scholar Rock Holding, Raises Price Target to $63
JP Morgan analyst Tessa Romero maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $56 to $63.
2 months ago benzinga.com
Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule
Scholar Rock shifts its FDA review for SMA treatment apitegromab to a secondary facility, keeping the September 30 approval date on schedule.
-
2 months ago benzinga.com
Wedbush Reiterates Outperform on Scholar Rock Holding, Maintains $58 Price Target
Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and maintains $58 price target.
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Scholar Rock Holding, Maintains $65 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $65 price target.
-
2 months ago benzinga.com
Citigroup Maintains Buy on Scholar Rock Holding, Raises Price Target to $60
Citigroup analyst Geoff Meacham maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $58 to $60.
-
2 months ago benzinga.com
Scholar Rock Removes Catalent Indiana From Apitegromab BLA After FDA OAI Classification; FDA Review Remains On Track for Sept. 30 PDUFA Using Second Fill-Finish Site
Today, August 7, 2026, Scholar Rock received customer notification from Catalent Indiana LLC (part of Novo Nordisk) that FDA classified the April 2026 site inspection of Catalent Indiana fill-finish…
-
2 months ago benzinga.com
Scholar Rock Holding Q2 EPS $(0.84) Beats $(0.85) Estimate; Cash Balance Of $492M
Scholar Rock Holding (NASDAQ:SRRK) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(0.85) by 1.18 percent. This is a 14.29 percent increase over losses of…
-
3 months ago benzinga.com
Wedbush Reiterates Outperform on Scholar Rock Holding, Maintains $58 Price Target
Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and maintains $58 price target.